PDCD1 and melanoma: In mice with B16-OVA melanoma, treatment with either aTim-3 or aPD-1 mAbs increased frequencies of OVA257-264 tetramer+ (tet+) and PD-1+Tim-3+tet+ CD8+ TILs as compared with IgG control mAbs, while higher frequencies were observed upon dual PD-1/Tim-3 blockade (Figure 8A and Supplemental Figure 6A).